ABVC BioPharma, Inc. - 10-Q Summary (Q2 2024)
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on developing plant-derived drugs and medical devices. The company operates through subsidiaries including BioLite, BioKey, and AiBtl BioPharma. As of August 14, 2024, there were 12,421,815 shares of common stock outstanding. The company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $118,347 | $134,381 |
| Net Loss | $(5,253,708) | $(4,212,455) |
| Net Loss Attributable to ABVC | $(4,945,621) | $(4,087,206) |
| Operating Expenses | $4,538,911 | $4,101,190 |
| Stock-Based Compensation | $2,957,736 | $592,229 |
| Interest Expense | $(944,715) | $(171,415) |
| Cash and Cash Equivalents | $124,296 | $60,155 |
| Restricted Cash | $618,473 | $656,625 |
| Total Current Assets | $2,189,567 | $1,656,709 |
| Total Current Liabilities | $6,548,927 | $5,932,490 |
| Working Capital Deficit | $(4,359,360) | $(4,275,781) |
| Convertible Notes Payable (Net) | $956,880 | $569,456 |
Material Changes vs. Prior Period
- Revenue: Decreased by 12% ($16,034) compared to the prior six-month period, primarily due to a decline in Contract Development and Manufacturing Organization (CDMO) services revenue, partially offset by milestone revenue from licensing agreements.
- Operating Expenses: Increased by 11% ($437,721). This was driven largely by a significant increase in stock-based compensation expenses ($2.36 million increase), related to employee and non-employee share-based payments.
- Net Loss: Increased by 25% ($1.04 million) to $5.25 million. The increase is attributed to higher operating expenses and a substantial rise in interest expense ($849,862 increase) due to the recognition of interest on convertible notes.
- Liquidity: Net cash used in operating activities decreased to $1.49 million from $2.40 million in the prior period, aided by licensing cash payments received and strict cash flow controls.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The company has reported a working capital deficit and net cash outflows from operations, raising substantial doubt about its ability to continue as a going concern. Management plans to raise additional capital through private or public offerings.
- NASDAQ Compliance: On July 10, 2024, the company received a notification that its stock price had been below $1.00 for 30 consecutive business days. The company has until January 6, 2025, to regain compliance, potentially via a reverse stock split.
- Licensing Agreements:
- ForSeeCon Eye Corporation (FEYE): Entered into a licensing agreement for ophthalmology products. Received 5 million FEYE shares (value uncertain) and $116,000 in cash milestone payments recognized as revenue.
- OncoX BioPharma: Signed three definitive agreements in April and May 2024 to license botanical drug extracts for lung, pancreatic, and myelodysplastic syndrome treatments. Payments are contingent on fundraising milestones and future sales.
- Convertible Notes: The company has outstanding convertible notes with Lind Global Fund II, LP. Significant interest expense was recognized due to accounting adjustments for converted notes. Warrants associated with these notes were exercised in May 2024.
- Related Party Transactions: Significant receivables exist from related parties (Rgene, BioFirst) dependent on their ability to collect licensing fees from third parties (OncoX, FEYE).
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of current cash ($124k) and restricted cash ($618k) against the working capital deficit and ongoing burn rate.
- Revenue Recognition: Confirm the valuation and realizability of the 5 million FEYE shares received as payment, which were not recognized as revenue due to uncertain fair value.
- Related Party Receivables: Assess the collectability of the $1.26 million due from related parties (Rgene, BioFirst), which is contingent on their success in securing funding from OncoX and FEYE.
- Debt Obligations: Review the terms of the Lind Global Fund II convertible notes, specifically the conversion prices, default triggers, and the impact of the $1.00 floor price amendment.
- NASDAQ Status: Monitor the company's progress in regaining compliance with the $1.00 minimum bid price requirement to avoid delisting.
- Stock-Based Compensation: Evaluate the sustainability of the high stock-based compensation expense ($2.96M for six months) and its impact on future dilution.